Publications

Detailed Information

Neurotrophin Receptors TrkA and TrkB in Retinoblastoma Are Differentially Expressed Depending on Cellular Differentiation

DC Field Value Language
dc.contributor.authorKim, Jeong Hun-
dc.contributor.authorKim, Jin Hyoung-
dc.contributor.authorKim, Dong Hun-
dc.contributor.authorCho, Chang Sik-
dc.contributor.authorYu, Young Suk-
dc.contributor.authorKim, Kyu-Won-
dc.contributor.authorJun, Hyoung-Oh-
dc.date.accessioned2012-06-29T08:59:36Z-
dc.date.available2012-06-29T08:59:36Z-
dc.date.issued2009-
dc.identifier.citationTUMOR BIOLOGY; Vol.30 ; 233-241ko_KR
dc.identifier.issn1010-4283-
dc.identifier.urihttps://hdl.handle.net/10371/78000-
dc.description.abstractRetinoblastoma is the most common primary intraocular malignancy in children. With the progression of retinoblastoma, retinoblastoma cells lose their ability to differentiate. Regardless of many attempts to identify prognostic factors in retinoblastoma, further investigation for prognostic factors of retinoblastoma progression is still required because of the lack of sensitivity and specificity of these prognostic factors in predicting disease progression. We demonstrated that the differential expression of the neurotrophin receptors TrkA and TrkB is closely related to the differentiation of retinoblastoma cells. While retinoblastoma cells expressed TrkA as well as TrkB, their growth rates were not influenced by the addition of nerve growth factor to the culture medium. In experimental animal models of retinoblastoma, TrkA expression was primarily detected in more differentiated areas with high nm23 immunoreactivity whereas TrkB expression was apparent in more proliferative areas with high Ki67 immunoreactivity. With retinoic-acid-induced differentiation of retinoblastoma cells, TrkA expression significantly increased whereas TrkB significantly decreased. The differential expression of TrkA and TrkB with differentiation of retinoblastoma cells was mediated by extracellular-signal-regulated kinase 1/2 activation, which was confirmed by immunocytochemistry of TrkA. Therefore, our results suggest that the differential expression of TrkA and TrkB could be valuable as a therapeutic target, for instance using specific inhibitors. Copyright (C) 2009 S. Karger AG, Baselko_KR
dc.description.sponsorshipThis study was supported by a grant from the National R&D
program for cancer control, Ministry of Health & Welfare, Republic
of Korea (800-20090246) and grant No. 04-2008-050 from
the Seoul National University Hospital Research.
ko_KR
dc.language.isoenko_KR
dc.publisherKARGERko_KR
dc.subjectDifferentiationko_KR
dc.subjectTrkBko_KR
dc.subjectExtracellular signal-regulated kinaseko_KR
dc.subjectRetinoblastomako_KR
dc.subjectTrkAko_KR
dc.titleNeurotrophin Receptors TrkA and TrkB in Retinoblastoma Are Differentially Expressed Depending on Cellular Differentiationko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김정훈-
dc.contributor.AlternativeAuthor김진형-
dc.contributor.AlternativeAuthor김동헌-
dc.contributor.AlternativeAuthor조창식-
dc.contributor.AlternativeAuthor전형오-
dc.contributor.AlternativeAuthor유영석-
dc.contributor.AlternativeAuthor김규원-
dc.identifier.doi10.1159/000243766-
dc.citation.journaltitleTUMOR BIOLOGY-
dc.description.citedreferenceKim JH, 2008, HUM PATHOL, V39, P1172, DOI 10.1016/j.humpath.2007.12.008-
dc.description.citedreferenceStephan H, 2008, PEDIATR BLOOD CANCER, V50, P218, DOI 10.1002/pbc.21369-
dc.description.citedreferenceKim JH, 2007, ONCOL REP, V18, P1373-
dc.description.citedreferenceKampmann E, 2007, NEUROSCI LETT, V426, P18, DOI 10.1016/j.neulet.2007.07.039-
dc.description.citedreferenceKim JH, 2007, INT J ONCOL, V31, P585-
dc.description.citedreferenceJohnson DA, 2007, CANCER RES, V67, P2701, DOI 10.1158/0008-5472.CAN-06-3754-
dc.description.citedreferenceLaurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194-
dc.description.citedreferenceKruttgen A, 2006, BRAIN PATHOL, V16, P304-
dc.description.citedreferenceClagett-Dame M, 2006, J NEUROBIOL, V66, P739, DOI 10.1002/neu.20241-
dc.description.citedreferenceChen D, 2004, CANCER CELL, V5, P539-
dc.description.citedreferenceLachyankar MB, 2003, J NEUROSCI RES, V71, P157, DOI 10.1002/jnr.10480-
dc.description.citedreferenceHo R, 2002, CANCER RES, V62, P6462-
dc.description.citedreferenceLillington DM, 2002, BRIT J CANCER, V87, P779, DOI 10.1038/sj.bjc.6600532-
dc.description.citedreferenceWagner N, 2000, INVEST OPHTH VIS SCI, V41, P1932-
dc.description.citedreferenceEggert A, 2000, ONCOGENE, V19, P2043-
dc.description.citedreferenceNag TC, 1999, DEV BRAIN RES, V117, P179-
dc.description.citedreferenceKimura N, 1996, ENDOCR PATHOL, V7, P281-
dc.description.citedreferenceKhelfaoui F, 1996, CANCER, V77, P1206-
dc.description.citedreferenceHOEHNER JC, 1995, AM J PATHOL, V147, P102-
dc.description.citedreferenceLAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727-
dc.description.citedreferenceMATSUMOTO K, 1995, CANCER RES, V55, P1798-
dc.description.citedreferenceBARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148-
dc.description.citedreferenceVERDI JM, 1994, NEURON, V12, P733-
dc.description.citedreferenceSHIELDS CL, 1994, CANCER, V73, P692-
dc.description.citedreferenceSHIELDS CL, 1993, BRIT J OPHTHALMOL, V77, P544-
dc.description.citedreferenceNAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847-
dc.description.citedreferenceKOPELMAN JE, 1987, OPHTHALMOLOGY, V94, P371-
dc.description.citedreferenceSQUIRE J, 1986, NATURE, V322, P555-
dc.description.citedreferenceLEE WH, 1984, NATURE, V309, P458-
dc.description.citedreferenceKNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820-
dc.description.tc0-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share